Share
Market Research Report

KETAMINE CLINIC MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026-2033)

Segmentation
  • By Therapy ModalityOn-Site/In-Clinic Therapy and Online Ketamine Therapy Consultation Services/Telehealth Therapy
  • By Clinical IndicationTreatment-resistant unipolar depression · Major depressive disorder with acute suicidal ideation/behavior · Bipolar depression · Post-traumatic stress disorder · Anxiety disorders · Obsessive-compulsive disorder · Substance use disorders (e.g., AUD) · Neuropathic pain (e.g., CRPS, diabetic neuropathy) · Chronic musculoskeletal pain (e.g., low back/osteoarthritis) · Fibromyalgia · Migraine/headache disorders · and Cancer-related/palliative pain
  • By Route of AdministrationOral · Parenteral · and Nasal
  • By Patient Age GroupAdolescents (13–17) · Adults (18–64) · and Geriatric (65+)
  • By Care TypeMedication-only and Ketamine-assisted psychotherapy
  • By Referral ChannelDirect-to-consumer or self-referred · Physician-referred (psychiatry/primary care) · and Payer/case-management referred
  • By Business ModelIndependently owned private clinic · Franchise-Owned clinics · Hospital affiliated clinics · Research and Clinical Trial Centers · and Others (Anesthesiology/psychology practice extension)
  • By GeographyNorth America · Europe · Asia Pacific · Latin America · Middle East · and Africa
  • Published In10 Mar 2026
  • Report CodeCMI8503
  • Pages250+
  • FormatsExcel and PDF
  • Base Year2025
  • Estimated Year2026
  • Historical Range2020 - 2024
  • Forecast Period2026-2033

Market Segmentation

  • Therapy Modality Insights (Revenue, USD Bn, 2021 - 2033)

    • On-Site/In-Clinic Therapy
    • Online Ketamine Therapy Consultation Services/Telehealth Therapy

  • Clinical Indication Insights (Revenue, USD Bn, 2021 - 2033)

    • Treatment-resistant unipolar depression
    • Major depressive disorder with acute suicidal ideation/behavior
    • Bipolar depression
    • Post-traumatic stress disorder
    • Anxiety disorders
    • Obsessive-compulsive disorder
    • Substance use disorders (e.g., AUD)
    • Neuropathic pain (e.g., CRPS, diabetic neuropathy)
    • Chronic musculoskeletal pain (e.g., low back/osteoarthritis)
    • Fibromyalgia
    • Migraine/headache disorders
    • Cancer-related/palliative pain

  • Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)

    • Oral
    • Parenteral
    • Nasal

  • Patient Age Group Insights (Revenue, USD Bn, 2021 - 2033)

    • Adolescents (13–17)
    • Adults (18–64)
    • Geriatric (65+)

  • Care Type Insights (Revenue, USD Bn, 2021 - 2033)

    • Medication-only
    • Ketamine-assisted psychotherapy

  • Referral Channel Insights (Revenue, USD Bn, 2021 - 2033)

    • Direct-to-consumer or self-referred
    • Physician-referred (psychiatry/primary care)
    • Payer/case-management referred

  • Business Model Insights (Revenue, USD Bn, 2021 - 2033)

    • Independently owned private clinic
    • Franchise-Owned clinics
    • Hospital affiliated clinics
    • Research and Clinical Trial Centers
    • Others (Anesthesiology/psychology practice extension)

  • Regional Insights (Revenue, USD Bn, 2021 - 2033)

    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa